Press release
Health Care
November 17, 2021

Evonik now offers customizable RESOMER® PrintPowder for 3D printing of personalized, implantable medical devices

  • Expands portfolio of bioresorbable polymers with customizable properties to support customer innovation
  • Maximizes material choice for customers using selective laser sintering (SLS) of medical devices  
  • Enables patient-specific devices and expands the use into new clinical applications


Essen, Germany. Evonik now offers a broader range of RESOMER® PrintPowder polymers to enable the 3D printing of personalized implantable medical devices. The new powders are available globally for 3D printing through selective laser sintering (SLS).

Thanks to a broader range of customizable mechanical properties and degradation rates, the new powders can be used for more complex and tailored medical devices including diverse orthopedic, dental, or soft tissue applications. Evonik also offers comprehensive SLS application and printing service support for the new powder types.

“We are proud that these new powders will allow manufacturers to create personalized devices with complex internal designs that match a patient’s anatomy – this will open up new treatment options for patients,” said Thomas Riermeier, Head of Evonik’s Health Care business line.   

Evonik is a market leader in medical grade powders for SLS printing, as well as offering bioresorbable filaments for FDM printing. The second generation of RESOMER® PrintPowder maximizes the choice for SLS printing of medical devices and widens application to more clinical indications. By expanding both its portfolio of GMP-grade bioresorbable polymers for SLS printing and its 3D printing services, Evonik’s Health Care business line is increasing its offering of bioresorbable materials for medical technology system solutions. The share of system solutions in the Nutrition & Care division, which is home to Evonik Health Care, is set to increase from 20 percent today to more than 50 percent by 2030.

The new polymer print powders build on the success of the first-generation free-flowing RESOMER® PrintPowder C 212 F. This powder, which was launched in 2020, is based on polycaprolactone and offers tight specifications and an optimized particle size distribution for SLS. In contrast, the new range of polymers, which are now available for sampling and customer evaluation, add polylactide or polydioxanone-based polymers into the portfolio for SLS printing.

3D printing is a versatile and precise way of producing medical implants. The development of additional materials for 3D printing allows health care providers and device manufacturers to bring new treatment options to the patients.

Evonik is a leading global solutions provider for innovative materials in the medical device and pharmaceutical markets. RESOMER®, now commercially available for more than 30 years, is the industry’s most comprehensive GMP (Good Manufacturing Practice) portfolio of standard, custom and specialized bioresorbable polymers for use with implantable medical devices and pharmaceutical drug products.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.